• Experience in the treatment of recurrent nonspecific vulvovaginitis

Experience in the treatment of recurrent nonspecific vulvovaginitis

HEALTH OF WOMAN. 2017.9(125):92–96; doi 10.15574/HW.2017.125.92

Kosilova S. E.
SHEIU «Bukovinsky State Medical University», Chernivtsi

Recurrent nonspecific vulvovaginitis is an actual medical and social problem, as it leads to the development of background and precancerous diseases of the cervix, endometritis, infertility, ectopic pregnancy, complicated course of gestation and childbirth.
The objective: was to study the clinical and microbiological efficacy of the local antiseptic Furasol and Lactagel, which promotes the growth of lactobacilli and the restoration of vaginal pH in the treatment of women with recurrent vulvovaginitis.
Materials and methods. A clinical and laboratory study of the efficacy of the combined use of the combined local antiseptic Furasol (furagin soluble – 0.1 g, sodium chloride 0.9 g) and vaginal gel Lactagel (lactic acid and glycogen) in the treatment of 25 women of childbearing age with chronic recurrent non-specific vulvovaginitis.
Results. The complex application of the furagin soluble (Furasol) plus Lactagel regimen for the treatment of recurrent nonspecific vulvovaginitis contributes to the effective sanitation of the vagina, the elimination of the inflammatory process and clinical symptoms, and the restoration of the lactobacillary biotope.
The conclusion. The combination of Furasol with Lactagel prevents the recurrence of unspecific vulvovaginitis in women of reproductive age.
Key words: chronic recurrent nonspecific vulvovaginitis, soluble furagin, Furasol, Lactagel.

References
1. Grishchenko OV. Lakhno IV. 2017. Povysheniye komplayentnosti lecheniya patsiyentok s bakterialnym vaginozom. Reproduktivna endokrinologіya 1(33):2–4. 
2. Lakhno IV. Grishchenko OV. 2016. Stupenchataya terapiya vaginalnogo disbioza: mozaika dokazatelstv. Reproduktivna endokrinologіya 2(28):58–59.

3. Markin LB, Shakhova OV. 2012. Efektyvnist zastosuvannia kombinatsii riznykh form vypusku antyseptyka z antymikrobnoiu aktyvnistiu Heksykonu v likuvanni zapalnykh zakhvoriuvan pikhvy. Zdorove zhenshchynы 2(68):188–190.

4. Radzinskiy VE. 2012. Infektologiya XXI veka: neprostyye otvety. Infektsii i infektsionnyy kontrol. Status Praesens. 2(8):5–7.

5. Senchuk AIa. 2013. Vyvchennia efektyvnosti ta bezpeky vykorystannia preparatu Vahiklin pry likuvanni bakterialnoho vahinozu ta nespetsyfichnoho vahinitu. Consilium medicum 7;5:11–13.

6. Yankovskyi DS, Shyrobokov VP, Antypkyn YuH, Tatarchuk TF, Dыment HS. 2015. Mykrobyom y zdorove zhenshchynы. Reproduktyvna endokrynolohiia. Almanakh reproduktyvnoho zdorov’ia: 26–48.

7. Carati D, Zizza A, Guido M et al. 2016. Safety, efficacy, and tolerability of differential trteatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women. Clin. Exp. Obstet Gynecol. 43;2:198–202. PMid:27132409

8. Sobel JD, Subramanian C, Foxman B et al. 2013. Mixed vaginitis – more than coinfection and with therapeoutic implications. Curr. Infect Dis. Rep. 15:104–108. https://doi.org/10.1007/s11908-013-0325-5; PMid:23354954